288 related articles for article (PubMed ID: 22564725)
1. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells.
Caldon CE; Sergio CM; Kang J; Muthukaruppan A; Boersma MN; Stone A; Barraclough J; Lee CS; Black MA; Miller LD; Gee JM; Nicholson RI; Sutherland RL; Print CG; Musgrove EA
Mol Cancer Ther; 2012 Jul; 11(7):1488-99. PubMed ID: 22564725
[TBL] [Abstract][Full Text] [Related]
2. Constitutive overexpression of cyclin D1 but not cyclin E confers acute resistance to antiestrogens in T-47D breast cancer cells.
Hui R; Finney GL; Carroll JS; Lee CS; Musgrove EA; Sutherland RL
Cancer Res; 2002 Dec; 62(23):6916-23. PubMed ID: 12460907
[TBL] [Abstract][Full Text] [Related]
3. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.
Scaltriti M; Eichhorn PJ; Cortés J; Prudkin L; Aura C; Jiménez J; Chandarlapaty S; Serra V; Prat A; Ibrahim YH; Guzmán M; Gili M; Rodríguez O; Rodríguez S; Pérez J; Green SR; Mai S; Rosen N; Hudis C; Baselga J
Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3761-6. PubMed ID: 21321214
[TBL] [Abstract][Full Text] [Related]
4. Functional ablation of pRb activates Cdk2 and causes antiestrogen resistance in human breast cancer cells.
Varma H; Skildum AJ; Conrad SE
PLoS One; 2007 Dec; 2(12):e1256. PubMed ID: 18060053
[TBL] [Abstract][Full Text] [Related]
5. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.
Etemadmoghadam D; Au-Yeung G; Wall M; Mitchell C; Kansara M; Loehrer E; Batzios C; George J; Ftouni S; Weir BA; Carter S; Gresshoff I; Mileshkin L; Rischin D; Hahn WC; Waring PM; Getz G; Cullinane C; Campbell LJ; Bowtell DD
Clin Cancer Res; 2013 Nov; 19(21):5960-71. PubMed ID: 24004674
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens.
Carroll JS; Swarbrick A; Musgrove EA; Sutherland RL
Cancer Res; 2002 Jun; 62(11):3126-31. PubMed ID: 12036924
[TBL] [Abstract][Full Text] [Related]
7. Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc.
Caldon CE; Sergio CM; Schütte J; Boersma MN; Sutherland RL; Carroll JS; Musgrove EA
Mol Cell Biol; 2009 Sep; 29(17):4623-39. PubMed ID: 19564413
[TBL] [Abstract][Full Text] [Related]
8. Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma.
Sonntag R; Giebeler N; Nevzorova YA; Bangen JM; Fahrenkamp D; Lambertz D; Haas U; Hu W; Gassler N; Cubero FJ; Müller-Newen G; Abdallah AT; Weiskirchen R; Ticconi F; Costa IG; Barbacid M; Trautwein C; Liedtke C
Proc Natl Acad Sci U S A; 2018 Sep; 115(37):9282-9287. PubMed ID: 30150405
[TBL] [Abstract][Full Text] [Related]
9. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
Chu I; Blackwell K; Chen S; Slingerland J
Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
[TBL] [Abstract][Full Text] [Related]
10. Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cells.
Kang J; Sergio CM; Sutherland RL; Musgrove EA
BMC Cancer; 2014 Jan; 14():32. PubMed ID: 24444383
[TBL] [Abstract][Full Text] [Related]
11. Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells.
Johnson N; Bentley J; Wang LZ; Newell DR; Robson CN; Shapiro GI; Curtin NJ
Br J Cancer; 2010 Jan; 102(2):342-50. PubMed ID: 20010939
[TBL] [Abstract][Full Text] [Related]
12. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
13. Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells.
Nair BC; Vallabhaneni S; Tekmal RR; Vadlamudi RK
Breast Cancer Res; 2011 Aug; 13(3):R80. PubMed ID: 21834972
[TBL] [Abstract][Full Text] [Related]
14. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.
Godinho M; Meijer D; Setyono-Han B; Dorssers LC; van Agthoven T
J Cell Physiol; 2011 Jul; 226(7):1741-9. PubMed ID: 21506106
[TBL] [Abstract][Full Text] [Related]
15. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Thrane S; Pedersen AM; Thomsen MB; Kirkegaard T; Rasmussen BB; Duun-Henriksen AK; Lænkholm AV; Bak M; Lykkesfeldt AE; Yde CW
Oncogene; 2015 Aug; 34(32):4199-210. PubMed ID: 25362855
[TBL] [Abstract][Full Text] [Related]
16. Cyclin E1 and cyclin E2 in ER+ breast cancer: prospects as biomarkers and therapeutic targets.
Milioli HH; Alexandrou S; Lim E; Caldon CE
Endocr Relat Cancer; 2020 May; 27(5):R93-R112. PubMed ID: 32061162
[TBL] [Abstract][Full Text] [Related]
17. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.
Watts CK; Brady A; Sarcevic B; deFazio A; Musgrove EA; Sutherland RL
Mol Endocrinol; 1995 Dec; 9(12):1804-13. PubMed ID: 8614416
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer.
Akli S; Zheng PJ; Multani AS; Wingate HF; Pathak S; Zhang N; Tucker SL; Chang S; Keyomarsi K
Cancer Res; 2004 May; 64(9):3198-208. PubMed ID: 15126360
[TBL] [Abstract][Full Text] [Related]
19. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition.
Au-Yeung G; Lang F; Azar WJ; Mitchell C; Jarman KE; Lackovic K; Aziz D; Cullinane C; Pearson RB; Mileshkin L; Rischin D; Karst AM; Drapkin R; Etemadmoghadam D; Bowtell DD
Clin Cancer Res; 2017 Apr; 23(7):1862-1874. PubMed ID: 27663592
[No Abstract] [Full Text] [Related]
20. Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest.
Dhillon NK; Mudryj M
Oncogene; 2002 Jul; 21(30):4626-34. PubMed ID: 12096339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
